Combining 2 targeted therapies results in melanoma patients living significantly longer

(ECCO-the European CanCer Organisation) Latest results from a trial of a combination of two targeted therapies (dabrafenib and trametinib) to treat advanced melanoma have shown that patients are living significantly longer on the combined therapy than patients treated with another drug, vemurafenib, when used alone.